Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT04428788 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04428788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04428788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2020
Completion date
October 28, 2025
Enrollment
131 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms